Just been looking at what's coming up for CI earnings and the numbers are pretty interesting. They're expecting about $7.87 per share, which would be up nearly 19% from last year, and revenue guidance sits around $69.93 billion (up 6.5% YoY). What caught my eye is how the estimates have stayed stable over the past month - no major revisions, which usually means the market's already priced this in.

The segment breakdown tells a different story though. Healthcare revenues are supposed to drop 17.9% while the pharmacy side jumps 12.2% and Evernorth Health Services climbs 10.1%. That's a pretty significant shift in the revenue mix. Medical care ratios for CI Healthcare are expected at 87.2%, down slightly from 87.9% last quarter, which could signal better operational efficiency.

Customer metrics show some pressure - total medical customers expected at 18.09 million versus 19.15 million last year. That's worth watching. On the stock side, CI has been down about 1.8% over the past month while the broader market gained 0.7%, so there's some underperformance there. With a Hold rating, this doesn't look like it's setting up for any major moves in the near term. Probably a decent earnings play if you're looking at the fundamentals, but nothing explosive on the horizon.